Literature DB >> 22592157

Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis.

Pierre-Antoine Gourraud1, Caroline Le Gall, Eve Puzenat, François Aubin, Jean-Paul Ortonne, Carle F Paul.   

Abstract

Although the demand for evidence-based decisions is increasing in clinical practice, recent systematic reviews on the accuracy of existing psoriasis severity scales, including the Psoriasis Area and Severity Index (PASI), suggest that their validity is not fully characterized. We simulated the evaluation of PASI by two practitioners in 1,000 sets of 100 patients. PASI data from several practitioners who examined the same patients were used to generate PASI scores by two practitioners, in order to compare how well commonly used statistics assess the inter-rater agreement for the PASI. Because the PASI score has an asymmetric distribution, statistics such as Pearson's linear correlation coefficient "r" and Spearman's rank correlation coefficient overestimated the inter-rater agreement of PASI as compared with the intra-class correlation coefficient (ICC; r=0.8, ρ=0.7, ICC=0.5). When restricting the analysis to patients with a PASI <20, inter-rater agreement severely decreased (r=0.38, ρ=0.41, ICC=0.17), resulting in unacceptable therapeutic decision agreement (κ=0.38). Our study indicates that owing to the skewed distribution of the PASI its validity to influence therapeutic decisions is questionable. The ICC is preferable to the commonly used statistics (r and ρ) for assessing the inter-rater agreement reliability of asymmetrically distributed scores such as the PASI.

Entities:  

Mesh:

Year:  2012        PMID: 22592157     DOI: 10.1038/jid.2012.124

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

Review 1.  Novel drug delivery strategies and gene therapy regimen as a promising perspective for management of psoriasis.

Authors:  Sujata Pralhad Sawarkar; Vijay Yadav
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

2.  Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis.

Authors:  Misha Rosenbach; Howa Yeung; Emily Y Chu; Ellen J Kim; Aimee S Payne; Junko Takeshita; Carmela C Vittorio; Karolyn A Wanat; Victoria P Werth; Joel M Gelfand
Journal:  JAMA Dermatol       Date:  2013-05       Impact factor: 10.282

Review 3.  Validation studies of outcome measures in pemphigus.

Authors:  Sarah Hanna; Minhee Kim; Dedee F Murrell
Journal:  Int J Womens Dermatol       Date:  2016-12-10

4.  Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay.

Authors:  Robert J Konrad; Richard E Higgs; George H Rodgers; Wenyu Ming; Yue-Wei Qian; Nicoletta Bivi; Justin K Mack; Robert W Siegel; Brian J Nickoloff
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

5.  Moderate Psoriasis in Clinical Practice: French Expert Consensus Using a Modified Delphi Method.

Authors:  Marie-Aleth Richard; François Aubin; Nathalie Beneton; Anne Bouloc; Anne-Claire Bursztejn; Vincent Descamps; Denis Jullien
Journal:  Adv Ther       Date:  2022-09-16       Impact factor: 4.070

6.  Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians.

Authors:  H Gilet; A Roborel de Climens; B Arnould; H Bachelez; M Bagot; P Beaulieu; P Joly; D Jullien; M Le Maître; J P Ortonne; C Paul; E Thibout
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-07-25       Impact factor: 6.166

7.  Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT).

Authors:  Kanokvalai Kulthanan; Leena Chularojanamontri; Papapit Tuchinda; Chuda Rujitharanawong; Marcus Maurer; Karsten Weller
Journal:  Health Qual Life Outcomes       Date:  2016-04-14       Impact factor: 3.186

8.  Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients.

Authors:  Kanokvalai Kulthanan; Leena Chularojanamontri; Chuda Rujitharanawong; Puncharas Weerasubpong; Karsten Weller; Marcus Maurer
Journal:  Biomed Res Int       Date:  2019-10-31       Impact factor: 3.411

9.  Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change.

Authors:  Kanokvalai Kulthanan; Leena Chularojanamontri; Chuda Rujitharanawong; Puncharas Weerasubpong; Marcus Maurer; Karsten Weller
Journal:  Health Qual Life Outcomes       Date:  2019-10-26       Impact factor: 3.186

10.  Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study.

Authors:  M-A Richard; J-P Lacour; M-P Konstantinou; M Ruer-Mulard; P Joly; S Aractingi; P Auquier; B Pelvet; M L Augustin; E Mahé; R J G Chalmers
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-10-02       Impact factor: 6.166

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.